RenovoRx Secures FDA Orphan Drug Designation for Pancreatic Cancer Drug Oxaliplatin
RNXT sits 35% above its 52-week low of $0.701.
Summary
RenovoRx has received FDA Orphan Drug Designation for oxaliplatin for the treatment of pancreatic cancer. This is the company's third ODD, and second for pancreatic cancer, validating its targeted intra-arterial drug delivery approach using the RenovoCath device. The designation provides significant regulatory and financial benefits, including seven years of market exclusivity upon approval, a 25% federal tax credit on clinical research, and a waiver of FDA application fees. This is a material positive development for the small-cap biotech, reducing development costs and enhancing the commercial potential of its pipeline in an area of high unmet medical need. The company continues to advance its Phase III TIGeR-PaC clinical trial and commercialize RenovoCath.
At the time of this announcement, RNXT was trading at $0.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $42M. The 52-week trading range was $0.70 to $1.45. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.